EGFR Inhibition with Cetuximab in Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)
Baselga J et al. Cetuximab + cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: Results of the randomized phase II BALI-1 trial. San Antonio Breast Cancer Symposium 2010;Abstract PD01-01.
Dr Burstein is Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.
|